Back
Lawrence P. Landwehr, MD
Respiratory Research Experience
Asthma
Denali - A 12-week, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT008 and PT007 Administered QID in Adults and Children 4 Years of Age or Older With Asthma. Adult/Child Asthma
AstraZeneca - A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to
Budesonide and Formoterol Fumarate MDI and Symbicort® Pressurized MDI in Adult and Adolescent Participants with
Inadequately Controlled Asthma (LOGOS) / Adult/Adolescent Asthma
GlaxoSmithKline - A Randomized, Double-blind, Parallel Group, Multicentre, Stratified, Study Evaluating the Efficacy and Safety of Once Daily Fluticasone Furoate/Vilanterol Inhalation Powder Compared to Once Daily Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Participants Aged 5 to 17 Years Old (inclusive) Currently Uncontrolled on Inhaled Corticosteroids. / Pediatric Asthma
TEVA/Compleware - A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg, in Adult Subjects with Asthma / Adult Asthma
West Ward Columbus, Inc/Pharm-Olam International - A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared with Advair Diskus® 100/50 in Subjects with Asthma / Adult/Adolescent Asthma
Novartis - A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039A2317 when added to standard-of care asthma therapy in patients with uncontrolled asthma / Adult/Adolescent Asthma
Chiesi - An 8-week, randomized, double-blind, placebo and active-controlled, parallel group, dose ranging study to evaluate the efficacy and safety of 3 doses of CHF 718 pMDI (beclomethasone dipropionate) in asthmatic subjects / Adult Asthma
Lupin - A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Clinical Study to Assess the Efficacy and Safety of Twice Daily Administration of Fluticasone Propionate and Salmeterol Inhalation Powder 100/50 mcg Compared to Administration of ADVAIR DISKUS® 100/50 mcg Twice Daily and Placebo in Patients 12 Years of Age and Older with Reversible Persistent Asthma including a 3-Week Open-Label Extension to Assess Inhaler Robustness Asthma / Adult/Adolescent Asthma
Parexel - A Randomized, Blinded, Parallel Group, Placebo Controlled, Multiple Dose, Multicenter, Multinational Study to Compare the Therapeutic Equivalence of a Budesonide 80 mcg/Formoterol Fumarate Dihydrate 4.5 mcg Inhalation Aerosol (manufactured by Catalent for Watson Laboratories Inc.) to Symbicort® (Budesonide 80 mcg/Formoterol Fumarate Dihydrate 4.5 mcg Inhalation Aerosol) (manufactured by AstraZeneca) in Adolescent and Adult Patients with Asthma / Adolescent/Adult Asthma
TEVA - A 12-week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years with Persistent Asthma / Adolescent Asthma
Merck - A phase III, randomized, active-controlled, parallel-group clinical trial to study the efficacy and long-term safety of mometasone furoate / formoterol fumarate (MF/F, MK-0887A [SCH418131]), compared with mometasone furoate (MF, MK-0887 [SCH032088]), in children with persistent asthma. / Adolescent Asthma
TEVA - A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older with Persistent Asthma /
Adult/Adolescent Asthma
TEVA - A Three-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Chronic-Dose Safety and Efficacy and Study of Albuterol Multi-Dose Dry Powder Inhaler (MDPI) relative to Placebo in Pediatric Asthmatics / Pediatric Asthma
Mylan - A Randomized, Double-Blind, Double Dummy, Parallel Group Study to Determine the Local Equivalence of Multiple Doses of MGR001 to ADVAIR® DISKUS® Administered Via Oral Inhalation In Adult Asthma Patients. / Adult Asthma
MEDA - A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 320 or 640 mcg/Day of Beclomethasone Dipropionate Delivered via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Adolescent and Adult Patients 12 Years of Age and Older / Adult/Adolescent Asthma
Lupin - A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Clinical Study to Assess the Efficacy and Safety of Twice Daily Administration of Fluticasone Propionate and Salmeterol Inhalation Powder 100/50 mcg Compared to Administration of ADVAIR DISKUS® 100/50 mcg Twice Daily and Placebo in Patients 12 Years of Age and Older with Reversible Persistent Asthma including a 3-Week Open-Label Extension to Assess Inhaler Robustness Asthma / Adult/Adolescent Asthma
Parexel - A Randomized, Blinded, Parallel Group, Placebo Controlled, Multiple Dose, Multicenter, Multinational Study to Compare the Therapeutic Equivalence of a Budesonide 80 mcg/Formoterol Fumarate Dihydrate 4.5 mcg Inhalation Aerosol (manufactured by Catalent for Watson Laboratories Inc.) to Symbicort® (Budesonide 80 mcg/Formoterol Fumarate Dihydrate 4.5 mcg Inhalation Aerosol) (manufactured by AstraZeneca) in Adolescent and Adult Patients with Asthma / Adolescent/Adult Asthma
TEVA - A 12-week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years with Persistent Asthma / Adolescent Asthma
Merck - A phase III, randomized, active-controlled, parallel-group clinical trial to study the efficacy and long-term safety of mometasone furoate / formoterol fumarate (MF/F, MK-0887A [SCH418131]), compared with mometasone furoate (MF, MK-0887 [SCH032088]), in children with persistent asthma. / Adolescent Asthma
TEVA - A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older with Persistent Asthma /
Adult/Adolescent Asthma
TEVA - A Three-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Chronic-Dose Safety and Efficacy and Study of Albuterol Multi-Dose Dry Powder Inhaler (MDPI) relative to Placebo in Pediatric Asthmatics / Pediatric Asthma
Mylan - A Randomized, Double-Blind, Double Dummy, Parallel Group Study to Determine the Local Equivalence of Multiple Doses of MGR001 to ADVAIR® DISKUS® Administered Via Oral Inhalation In Adult Asthma Patients. / Adult Asthma
MEDA - A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 320 or 640 mcg/Day of Beclomethasone Dipropionate Delivered via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Adolescent and Adult Patients 12 Years of Age and Older / Adult/Adolescent Asthma
Vectura - randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to evaluate the efficacy and safety of three strengths of fluticasone propionate inhaled from a new dry powder inhaler in adolescent and adult subjects with asthma /Adult Adolescent Asthma
Novartis - A randomized, placebo-controlled, dose-ranging, multi-centre trial of QAW039 (1- 450 mg p.o.) to investigate the effect on FEV1 and ACQ in patients with moderate-to-severe, persistent, allergic asthma, inadequately controlled with ICS therapy / Adult Asthma
GSK/Parexel - A 6-month safety and benefit study of inhaled fluticasone propionate/ salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with persistent asthma / Peds Asthma
Merck - A 12-Week, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Mometasone Furoate Metered Dose Inhaler in the Treatment of Children Ages 5-11 Years With Persistent Asthma / Pediatric Asthma
Boehringer Ingelheim - A Phase II randomised, doubleblind, placebo-controlled, incomplete crossover tiral with 4-week treatment periods to evaluate efficacy and safety of tiotropium inhalation solution (doses 1.25 µg, 2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in the evening in adolescents (12 to 17 yrs old) with moderate persistent asthma. / Adolescent Asthma
Novartis - A randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to assess the efficacy and safety of different doses of indacaterol in adult patients with persistent asthma, using salmeterol as an active control / Adult Asthma
Novartis - A randomized, multi-center, parallel group, double blind, study to assess the safety of QMF Twisthaler® (500/400 µg) and mometasone furoate Twisthaler® (400µg) in adosescent and adult patients with persistent asthma. / Asthma
GSK - A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 100mcg Twice Daily compared with Placebo for 8 weeks in Adolescent and Adult Subjects with persistent Asthma Symptomatic on Non-Steroidal, Asthma Therapy / Asthma
Genentech, Inc - A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of HAE1 (PRO98498) in Subjects with Moderate to Severe Allergic Asthma / Asthma
Merck - A Multicenter, Randomized, Double-blind, Placebo-Controlled Parallel Group 8-Week Study to Evaluate the Efficacy and Safety of Chewable Montelukast When Initiated at the Start of the School year in Pediatric Patients With Chronic Asthma /
Pediatric Asthma
GlaxoSmithKline - A Randomized, Parallel Group, Double-Blind, Comparative Trial assessing Lung Function and Other Measures of Asthma Control in Adults and Adolescents, at least 12 years of Age, with Persistent Asthma, who have either a B16-Arg/Arg, a B16-Gly/Gly Genotype and are treated with Fluticasone Propionate/Salmeterol DISKUS Combination Product100/50mcg or Salmeterol DISKUS 50mcg / Adult/Adolescent Asthma
GlaxoSmithKline (add on site) - Multicenter, randomized, double-blind, double dummy, placebo-controlled, parallel group, clinical trial of treatment with an Inhalation Aerosol and placebo administered for four weeks in subjects with Symptoms of Asthma or Reactive Airways Disease age 6 to 23 months / Pediatric Asthma 6-23 months
Novartis - A randomized, placebo-controlled, dose-ranging, multi-centre trial of QAW039 (1- 450 mg p.o.) to investigate the effect on FEV1 and ACQ in patients with moderate-to-severe, persistent, allergic asthma, inadequately controlled with ICS therapy / Adult Asthma
GSK/Parexel - A 6-month safety and benefit study of inhaled fluticasone propionate/ salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with persistent asthma / Peds Asthma
Merck - A 12-Week, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Mometasone Furoate Metered Dose Inhaler in the Treatment of Children Ages 5-11 Years With Persistent Asthma / Pediatric Asthma
Boehringer Ingelheim - A Phase II randomised, doubleblind, placebo-controlled, incomplete crossover tiral with 4-week treatment periods to evaluate efficacy and safety of tiotropium inhalation solution (doses 1.25 µg, 2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in the evening in adolescents (12 to 17 yrs old) with moderate persistent asthma. / Adolescent Asthma
Novartis - A randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to assess the efficacy and safety of different doses of indacaterol in adult patients with persistent asthma, using salmeterol as an active control / Adult Asthma
Novartis - A randomized, multi-center, parallel group, double blind, study to assess the safety of QMF Twisthaler® (500/400 µg) and mometasone furoate Twisthaler® (400µg) in adosescent and adult patients with persistent asthma. / Asthma
GSK - A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation powder 100mcg Twice Daily compared with Placebo for 8 weeks in Adolescent and Adult Subjects with persistent Asthma Symptomatic on Non-Steroidal, Asthma Therapy / Asthma
Genentech, Inc - A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of HAE1 (PRO98498) in Subjects with Moderate to Severe Allergic Asthma / Asthma
Merck - A Multicenter, Randomized, Double-blind, Placebo-Controlled Parallel Group 8-Week Study to Evaluate the Efficacy and Safety of Chewable Montelukast When Initiated at the Start of the School year in Pediatric Patients With Chronic Asthma /
Pediatric Asthma
GlaxoSmithKline - A Randomized, Parallel Group, Double-Blind, Comparative Trial assessing Lung Function and Other Measures of Asthma Control in Adults and Adolescents, at least 12 years of Age, with Persistent Asthma, who have either a B16-Arg/Arg, a B16-Gly/Gly Genotype and are treated with Fluticasone Propionate/Salmeterol DISKUS Combination Product100/50mcg or Salmeterol DISKUS 50mcg / Adult/Adolescent Asthma
GlaxoSmithKline (add on site) - Multicenter, randomized, double-blind, double dummy, placebo-controlled, parallel group, clinical trial of treatment with an Inhalation Aerosol and placebo administered for four weeks in subjects with Symptoms of Asthma or Reactive Airways Disease age 6 to 23 months / Pediatric Asthma 6-23 months
AstraZeneca - A 12-Week, Randomized, Double-Blind, Double-Dummy Active-Controlled Study of SYMBICORT® pMDI Administered Once Daily in Children and Adolescents 6-15 yrs. Of age with Asthma / Adult Asthma
Merck - A Multicenter, Double-Blind, Randomized, Parallel- Group Study Investigating the Clinical Effect of L-000888839 in
Patients With Seasonal Allergic Rhinitis-a Pilot Study During the Fall Season / Adult Fall SAR
AstraZeneca - “A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial of Symbicort™ (80/4/5 mcg) versus its Mono-Products (budesonide and formoterol) in Children (> 6 Years of Age) and Adults with Asthma.” / Pediatric Asthma
GlaxoSmithKline - “A Randomized, Double-Blind, Parallel Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88mcg versus Placebo in Propellant GR106642X in Pediatric Subjects 4-11 Years of Age with Asthma” / Pediatric Asthma
Forest Laboratories, Inc. - “A Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Once-Daily Flunisolide FHA Inhaler System in Patients with Asthma Currently Treated with Inhaled Steroids” / Asthma
Sepracor Inc. - “An Efficacy, Safety, and Tolerability Study of Daily Dosing with Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects 2 to 5 years Old with Asthma” / Pediatric Asthma
Glaxo Wellcome - “A Randomized, Double-Blind, Double-Dummy, Parallel Group Comparison of Fluticasone Propionate Inhalation Powder (50 mcg BID) via DISKUS with Oral Montelukast (5 mg QD) Chewable Tablets in Children 6-12 years of Age with Persistent Asthma” / Pediatric Asthma
Aventis Pharmaceuticals Inc. - "A Multicenter, Double-Blind, Randomized, Parallel Groups, Placebo-Controlled Pilot Study To Observe The Effects of Montelukast 10 mg in Combination With Fexofenadine 180 mg Daily or 120 mg BID On Asthma In Subjects With Persistent Mild to Moderate Atopic Asthma" / Asthma
Schering-Plough Research Institute - “Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate HFA-227 Metered Dose Inhaler (MF-MDI) in the Treatment of Asthma in Children Previously Maintained on Inhaled Corticosteroids” / Pediatric Asthma
Merck & Co., Inc. - “A Randomized, Double-Blind Multicenter Study to Evaluate the Effect of Adding EitherMontelukast Sodium or Salmeterol Xinafoate to Inhaled Fluticasone in Adult Asthmatics” / Adult Asthma
Glaxo Wellcome - “A Randomized, Double-Blind, Parallel Group, Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg DISKUS Inhaler BID versus Fluticasone Propionate 250mcg DISKUS Inhaler BID in Adolescents and Adults with Moderate Persistent Asthma” / Adult/Adolescent Asthma
Forest Laboratories - “A Double-Blind, Placebo Controlled, Long Term Growth Study of HFA Flunisolide in Children with Mild Asthma” / Pediatric Asthma
Integrated Therapeutics/Schering-Plough Corp - “A Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Mometasone Furoate DPI and Fluticasone DPI in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Corticosteroids” / Asthma
Merck - A Multicenter, Double-Blind, Randomized, Parallel- Group Study Investigating the Clinical Effect of L-000888839 in
Patients With Seasonal Allergic Rhinitis-a Pilot Study During the Fall Season / Adult Fall SAR
AstraZeneca - “A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial of Symbicort™ (80/4/5 mcg) versus its Mono-Products (budesonide and formoterol) in Children (> 6 Years of Age) and Adults with Asthma.” / Pediatric Asthma
GlaxoSmithKline - “A Randomized, Double-Blind, Parallel Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88mcg versus Placebo in Propellant GR106642X in Pediatric Subjects 4-11 Years of Age with Asthma” / Pediatric Asthma
Forest Laboratories, Inc. - “A Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Once-Daily Flunisolide FHA Inhaler System in Patients with Asthma Currently Treated with Inhaled Steroids” / Asthma
Sepracor Inc. - “An Efficacy, Safety, and Tolerability Study of Daily Dosing with Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects 2 to 5 years Old with Asthma” / Pediatric Asthma
Glaxo Wellcome - “A Randomized, Double-Blind, Double-Dummy, Parallel Group Comparison of Fluticasone Propionate Inhalation Powder (50 mcg BID) via DISKUS with Oral Montelukast (5 mg QD) Chewable Tablets in Children 6-12 years of Age with Persistent Asthma” / Pediatric Asthma
Aventis Pharmaceuticals Inc. - "A Multicenter, Double-Blind, Randomized, Parallel Groups, Placebo-Controlled Pilot Study To Observe The Effects of Montelukast 10 mg in Combination With Fexofenadine 180 mg Daily or 120 mg BID On Asthma In Subjects With Persistent Mild to Moderate Atopic Asthma" / Asthma
Schering-Plough Research Institute - “Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate HFA-227 Metered Dose Inhaler (MF-MDI) in the Treatment of Asthma in Children Previously Maintained on Inhaled Corticosteroids” / Pediatric Asthma
Merck & Co., Inc. - “A Randomized, Double-Blind Multicenter Study to Evaluate the Effect of Adding EitherMontelukast Sodium or Salmeterol Xinafoate to Inhaled Fluticasone in Adult Asthmatics” / Adult Asthma
Glaxo Wellcome - “A Randomized, Double-Blind, Parallel Group, Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg DISKUS Inhaler BID versus Fluticasone Propionate 250mcg DISKUS Inhaler BID in Adolescents and Adults with Moderate Persistent Asthma” / Adult/Adolescent Asthma
Forest Laboratories - “A Double-Blind, Placebo Controlled, Long Term Growth Study of HFA Flunisolide in Children with Mild Asthma” / Pediatric Asthma
Integrated Therapeutics/Schering-Plough Corp - “A Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Mometasone Furoate DPI and Fluticasone DPI in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Corticosteroids” / Asthma
Schering-Plough Research Institute - “Placebo-Controlled Efficacy and Safety Study of Mometasone Furiate Dry Powder Inhaler (MF-DPI) in the Treatment of Asthma in Children Previously Maintained on Inhaled Corticosteroids” / Pediatric Asthma
Schering-Plough - "Placebo-Controlled, Dose-Ranging Study of Mometasone Furoate HFA-227 Metered Dose Inhaler (MDI) Compared to Beclomethasone Dipropionate (Vanceril 84 mcg Double Strength) in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Corticosteroids" / Asthma
Schering-Plough - "Placebo-Controlled, Dose-Ranging Study of Mometasone Furoate HFA-227 Metered Dose Inhaler (MDI) Compared to Beclomethasone Dipropionate (Vanceril 84 mcg Double Strength) in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Corticosteroids" / Asthma
Allergic Rhinitis Research Experience
Alk Abello - A one-year placbo-controlled phase III trial evaluating the efficacy and safety of the house dust mite (HDM) SLIT-tablet in children (5-11 years of age) with HDM allergic rhinitis/rhinoconjunctivitis with or without asthma / Pediatric SAR
Glenmark - A Double-Blind, Randomized Parallell-Group Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Dose Comination GSP 301 nasal Spray Compared With Placebo Nasal Spray in Pediatric Subjects (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR) / Pediatric SAR
Circassia - A Combined Phase 2b/3 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study to Assess the Efficacy and Safety of Grass-SPIRE in Subjects with Grass Pollen-Induced Allergic Rhinitis, with or without Conjunctivitis /
Adult/Adolescent SAR
Merck - A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (ambrosia artemisiifolia) Sublingual Immunotherapy Tablet, in children With A History of Ragweed-Induced rhinoconjunctivitis With or Without Asthma. / Peds Rhinoconjunctivitis
Circassia - A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects with a History of House Dust Mite-Induced Rhinoconjunctivitis / Adult Rhinoconjunctivitis
MEDA - "Randomized, Double-Blind Trial of the Safety and Efficacy of Dymista Nasal Spray Compared to Placebo Nasal Spray in the Treatment of Children Ages ≥4 years to <12 years with Seasonal Allergic Rhinitis" / Pediatric SAR
MEDA - Randomized Trial of the Safety of Dymista Nasal Spray and Fluticasone Propionate Nasal Spray in Children Ages ≥4 years to <12 years with Allergic Rhinitis / Pediatric SAR
TEVA - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study Designed to Assess the Efficacy and Safety of BDP Nasal Aerosol (80mcg, once daily) in Pediatric Subjects (4 to 11 Years of Age) with Perennial Allergic Rhinitis (PAR) / Pediatric PAR
Merck - A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite Induced AllergicRhinitis/Rhinoconjunctivitis With or Without Asthma / Adult/Child SLIT PAR
Sunovion - A 12-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years with Perennial Allergic Rhinitis / Pediatric PAR
Merck - A 28-Day Study Evaluating the Safety of Short Ragweed (Ambrosia artemisifolia) Allergy Immunotherapy Tablet (SCH 39641) Treatment in Subjects 18 years of age and older (Phase 2, Protocol No. P05751) / Adult SAR
Circassia - An Observational Multi-Centre Field Study to Assess Symptom Scores and Rescue Medication Usage in Subjects with a History of Ragweed Allergen-Induced Rhinoconjunctivitis / SAR
Merck - A Multicente, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum prantense) Sublingual Tablet (SCH 697243) in subjects at Least 5 Years of Age, with a History of Grass Pollen-Induced Rhinoconjunctivitis, With or Without Asthma./ Pediatric SAR
TEVA - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Finding Study To Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Pediatric Subjects (6 to 11 years of age) With Seasonal Allergic Rhinitis (SAR) / Pediatric SAR
Alcon - Safety of PATANASE® Nasal Spray in Patients with Perennial Allergic Rhinitis / Adult Adolescent PAR
Schering Plough - A Multicenter, Double-Blind, Random ized, Placebo-Controlled, Parallel-Group Sutdy of Ragweed Sublingual Tablet in Adult Subjects with A History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma / Ragweed SLIT
Stallergene - A randomized, double-blind, placebo-controlled, multi-center, Phase III study of the efficacy and safety of 300 IR sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to adult patients suffering from grass pollen rhinoconjunctivitis. / Adult SLIT
GlaxoSmithKline - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Effects of a One-Year Course of Fluticasone Furoate Nasal Spray 110mcg QD on Growth in Pre-Pubescent, Pediatric Subjects with Perennial Allergic Rhinitis / Pediatric PAR
Schering Plough Observation - A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Sublingual Immunotherapy With SCH 697243 (Phleum Pratense) in Children 5 to <18 Years of Age With A History of Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma / Pediatric SAR
Glenmark - A Double-Blind, Randomized Parallell-Group Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Dose Comination GSP 301 nasal Spray Compared With Placebo Nasal Spray in Pediatric Subjects (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR) / Pediatric SAR
Circassia - A Combined Phase 2b/3 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study to Assess the Efficacy and Safety of Grass-SPIRE in Subjects with Grass Pollen-Induced Allergic Rhinitis, with or without Conjunctivitis /
Adult/Adolescent SAR
Merck - A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (ambrosia artemisiifolia) Sublingual Immunotherapy Tablet, in children With A History of Ragweed-Induced rhinoconjunctivitis With or Without Asthma. / Peds Rhinoconjunctivitis
Circassia - A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects with a History of House Dust Mite-Induced Rhinoconjunctivitis / Adult Rhinoconjunctivitis
MEDA - "Randomized, Double-Blind Trial of the Safety and Efficacy of Dymista Nasal Spray Compared to Placebo Nasal Spray in the Treatment of Children Ages ≥4 years to <12 years with Seasonal Allergic Rhinitis" / Pediatric SAR
MEDA - Randomized Trial of the Safety of Dymista Nasal Spray and Fluticasone Propionate Nasal Spray in Children Ages ≥4 years to <12 years with Allergic Rhinitis / Pediatric SAR
TEVA - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study Designed to Assess the Efficacy and Safety of BDP Nasal Aerosol (80mcg, once daily) in Pediatric Subjects (4 to 11 Years of Age) with Perennial Allergic Rhinitis (PAR) / Pediatric PAR
Merck - A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite Induced AllergicRhinitis/Rhinoconjunctivitis With or Without Asthma / Adult/Child SLIT PAR
Sunovion - A 12-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years with Perennial Allergic Rhinitis / Pediatric PAR
Merck - A 28-Day Study Evaluating the Safety of Short Ragweed (Ambrosia artemisifolia) Allergy Immunotherapy Tablet (SCH 39641) Treatment in Subjects 18 years of age and older (Phase 2, Protocol No. P05751) / Adult SAR
Circassia - An Observational Multi-Centre Field Study to Assess Symptom Scores and Rescue Medication Usage in Subjects with a History of Ragweed Allergen-Induced Rhinoconjunctivitis / SAR
Merck - A Multicente, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum prantense) Sublingual Tablet (SCH 697243) in subjects at Least 5 Years of Age, with a History of Grass Pollen-Induced Rhinoconjunctivitis, With or Without Asthma./ Pediatric SAR
TEVA - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Finding Study To Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Pediatric Subjects (6 to 11 years of age) With Seasonal Allergic Rhinitis (SAR) / Pediatric SAR
Alcon - Safety of PATANASE® Nasal Spray in Patients with Perennial Allergic Rhinitis / Adult Adolescent PAR
Schering Plough - A Multicenter, Double-Blind, Random ized, Placebo-Controlled, Parallel-Group Sutdy of Ragweed Sublingual Tablet in Adult Subjects with A History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma / Ragweed SLIT
Stallergene - A randomized, double-blind, placebo-controlled, multi-center, Phase III study of the efficacy and safety of 300 IR sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to adult patients suffering from grass pollen rhinoconjunctivitis. / Adult SLIT
GlaxoSmithKline - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Effects of a One-Year Course of Fluticasone Furoate Nasal Spray 110mcg QD on Growth in Pre-Pubescent, Pediatric Subjects with Perennial Allergic Rhinitis / Pediatric PAR
Schering Plough Observation - A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Sublingual Immunotherapy With SCH 697243 (Phleum Pratense) in Children 5 to <18 Years of Age With A History of Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma / Pediatric SAR
Alcon - Safety and Efficacy of Olopatadine HCI Nasal Spray in 6-11 Year Old Patients / Pediatric SAR
GlaxoSmithKline - A comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis / SAR
Curalogic - A Randomized, Double-blind, Parallel Group, Placebo-Controlled Study To Assess The Efficacy And Safety Of Oral Microencapsulated Ragweed Pollen Extract Administered Prior To And During The Ragweed Pollen Season / Ragweed SAR
ALK/Abello - A phase III trial assessing the efficacy and safety of Grazax in subjects with seasonal grass pollen induced rhinoconjunctivitis with or without asthma / SAR
Alcon - Safety Study of Olopatadine Nasal Spray (add on site) / PAR
Apotex, Inc. - Double-Blind Multi-Center, Placebo-controlled, Clinical Study to Evaluate the Clinical Equivalence of 128 mcg of Budesonide Nasal Spray (Apotes Inc.,Candada) vs. 128 mcg of Rhinocort Aqua® Nasal spray (AstraZeneca, USA) for the Indication of Seasonal Allergic Rhinitis / SAR
Dynavax/CRN - A Phase III, Randomized, Double-Blind, Placebo Controlled, Multicenter Study of the Efficacy and Safety of Subcutaneously Administered TOLAMBA™ in Ragweed-Allergic Adults / Fall Ragweed
Apotex/AAI - A Bioequivalence study of 200 mcg of mometasone furoate nasal spray (Apotex Inc., Canada) vs. 200 mcg of Nasonex® nasal spray (Schering Corporation, USA) in patients with seasonal allergic rhinitis / Fall SAR
Clay-Park Labs, Inc. - An Investigator-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Demonstrate The Safety and Bioequivalence of Triaminolone Acetonide Nasal Spray [AGIS Industries (1983) LTD.] Compared with Nasacort AQ® Nasal Spray 55 Mcg (Aventis) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis (SAR). / SAR
GlaxoSmithKline - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg and 100mcg for 2 weeks in Pedicatric Subjects Ages 2 to <12 Years with Seasonal Allergic Rhinitis(SAR) / Peds SAR
GlaxoSmithKline - A comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis / SAR
Curalogic - A Randomized, Double-blind, Parallel Group, Placebo-Controlled Study To Assess The Efficacy And Safety Of Oral Microencapsulated Ragweed Pollen Extract Administered Prior To And During The Ragweed Pollen Season / Ragweed SAR
ALK/Abello - A phase III trial assessing the efficacy and safety of Grazax in subjects with seasonal grass pollen induced rhinoconjunctivitis with or without asthma / SAR
Alcon - Safety Study of Olopatadine Nasal Spray (add on site) / PAR
Apotex, Inc. - Double-Blind Multi-Center, Placebo-controlled, Clinical Study to Evaluate the Clinical Equivalence of 128 mcg of Budesonide Nasal Spray (Apotes Inc.,Candada) vs. 128 mcg of Rhinocort Aqua® Nasal spray (AstraZeneca, USA) for the Indication of Seasonal Allergic Rhinitis / SAR
Dynavax/CRN - A Phase III, Randomized, Double-Blind, Placebo Controlled, Multicenter Study of the Efficacy and Safety of Subcutaneously Administered TOLAMBA™ in Ragweed-Allergic Adults / Fall Ragweed
Apotex/AAI - A Bioequivalence study of 200 mcg of mometasone furoate nasal spray (Apotex Inc., Canada) vs. 200 mcg of Nasonex® nasal spray (Schering Corporation, USA) in patients with seasonal allergic rhinitis / Fall SAR
Clay-Park Labs, Inc. - An Investigator-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Demonstrate The Safety and Bioequivalence of Triaminolone Acetonide Nasal Spray [AGIS Industries (1983) LTD.] Compared with Nasacort AQ® Nasal Spray 55 Mcg (Aventis) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis (SAR). / SAR
GlaxoSmithKline - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg and 100mcg for 2 weeks in Pedicatric Subjects Ages 2 to <12 Years with Seasonal Allergic Rhinitis(SAR) / Peds SAR
ITGI, Inc. - Efficay and Safety of Desloratadine, Fexofenadine 180 mg. and Placebo in the Treatment of Subjects with Symptomatic Seasonal allergic Rhinitis (SAR) / Adult SAR
DYNAVAX Technologies Corp. - A Phase II Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Subcutaneously Administered Dynavax Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate (AIC) in Ragweed-Allergic Adults / Adult Ragweed
Merck & Co., Inc. - A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis / Adult/Adolescent PAR
Pfizer, Inc. - “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Zyrtec D-12 hour™ (Cetirizine HCL/Pseudoephedrine HCL) Versus Placebo in Patients with Seasonal Allergic Rhinitis and Concomitant Mild to Moderate Asthma” / SAR
Merck & Co., Inc. - “A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study Investigating the Clinical Effects of Montelukast in Patients with Perennial Allergic Rhinitis” / PAR
Aventis Pharmaceuticals - “A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Study to Assess the Safety and Tolerability of Fexofenadine HCL 30mg in Children with Allergic Rhinitis”. / Pediatric Allergic Rhinitis
Aventis Pharmaceuticals - “A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Study to Assess the Safety and Tolerability of Fexofenadine HCL 15mg in Children with Allergic Rhinitis”. / Pediatric Allergic Rhinitis
Roxane Laboratories Inc. - “A Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study Comparing the Efficacy and Safety of Generic Fluticasone Propionte Aqueous Nasal Spray vs. Flonase® Nasal Spray vs. Placebo Nasal Spray in Subjects with Seasonal Allergic Rhinitis” / SAR
Pfizer, Inc. - "A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of The Efficacy and Safety of Zyrtec Syrup vs. Placebo in the Treatment of Children with Seasonal Allergic Rhinitis” / Pediatric SAR
Schering-Plough - “Efficacy and Safety of Two Formulations of SCH 483 5/240 mg Compared to Desloratadine 5 mg and Pseudoephedrine 240 mg QD Sustained Release, in the Treatment of Subject With Seasonal Allergic Rhinitis” / SAR
Aventis Pharmaceuticals Inc. - "A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study To Assess The Safety And Tolerability Of Fexofenadine HCl 30 mg Twice A Day During Treatment Of Children 2 Through 5 Years Of Age With Allergic Rhinitis” / Pediatric Allergic Rhinitis
Merck & Co. - “A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Combination Montelukast/Loratadine in Patients with Seasonal Allergic Rhinitis-Fall-Study" / SAR
Aventis Pharmaceuticals Inc. - “A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study To Assess The Safety And Tolerability Of Fexofenadine HCl 30 mg Twice A Day During Treatment Of Children 2 Through 5 Years Of Age With Allergic Rhinitis” / Pediatric Allergic Rhinitis
Merck & Co., Inc. - “A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Combination Montelukast/Loratadine in Patients with Seasonal Allergic Rhinitis-Fall Study" / SAR
Hoeschst Marion Roussel - "A Double-Blind, Randomized, Placebo-Controlled, Parallel Study Comparing the Efficacy and Safety of Fexofenadine HCl 120 and 180 mg QD in the Treatment of Autumn Seasonal Allergic Rhinitis" / SAR
DYNAVAX Technologies Corp. - A Phase II Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Subcutaneously Administered Dynavax Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate (AIC) in Ragweed-Allergic Adults / Adult Ragweed
Merck & Co., Inc. - A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis / Adult/Adolescent PAR
Pfizer, Inc. - “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Zyrtec D-12 hour™ (Cetirizine HCL/Pseudoephedrine HCL) Versus Placebo in Patients with Seasonal Allergic Rhinitis and Concomitant Mild to Moderate Asthma” / SAR
Merck & Co., Inc. - “A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study Investigating the Clinical Effects of Montelukast in Patients with Perennial Allergic Rhinitis” / PAR
Aventis Pharmaceuticals - “A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Study to Assess the Safety and Tolerability of Fexofenadine HCL 30mg in Children with Allergic Rhinitis”. / Pediatric Allergic Rhinitis
Aventis Pharmaceuticals - “A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Study to Assess the Safety and Tolerability of Fexofenadine HCL 15mg in Children with Allergic Rhinitis”. / Pediatric Allergic Rhinitis
Roxane Laboratories Inc. - “A Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study Comparing the Efficacy and Safety of Generic Fluticasone Propionte Aqueous Nasal Spray vs. Flonase® Nasal Spray vs. Placebo Nasal Spray in Subjects with Seasonal Allergic Rhinitis” / SAR
Pfizer, Inc. - "A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of The Efficacy and Safety of Zyrtec Syrup vs. Placebo in the Treatment of Children with Seasonal Allergic Rhinitis” / Pediatric SAR
Schering-Plough - “Efficacy and Safety of Two Formulations of SCH 483 5/240 mg Compared to Desloratadine 5 mg and Pseudoephedrine 240 mg QD Sustained Release, in the Treatment of Subject With Seasonal Allergic Rhinitis” / SAR
Aventis Pharmaceuticals Inc. - "A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study To Assess The Safety And Tolerability Of Fexofenadine HCl 30 mg Twice A Day During Treatment Of Children 2 Through 5 Years Of Age With Allergic Rhinitis” / Pediatric Allergic Rhinitis
Merck & Co. - “A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Combination Montelukast/Loratadine in Patients with Seasonal Allergic Rhinitis-Fall-Study" / SAR
Aventis Pharmaceuticals Inc. - “A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study To Assess The Safety And Tolerability Of Fexofenadine HCl 30 mg Twice A Day During Treatment Of Children 2 Through 5 Years Of Age With Allergic Rhinitis” / Pediatric Allergic Rhinitis
Merck & Co., Inc. - “A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Combination Montelukast/Loratadine in Patients with Seasonal Allergic Rhinitis-Fall Study" / SAR
Hoeschst Marion Roussel - "A Double-Blind, Randomized, Placebo-Controlled, Parallel Study Comparing the Efficacy and Safety of Fexofenadine HCl 120 and 180 mg QD in the Treatment of Autumn Seasonal Allergic Rhinitis" / SAR
Device Study
GlaxoSmithKline - An open-label study to evaluate the correct use of placebo ELLIPTA™ dry powder inhaler (DPI) compared to placebo metered dose inhalers (MDI) in subjects with moderate persistent asthma / Adult/Adolescent Device
Asthma/Allergy
GlaxoSmithKline - A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD versus Montelukast 10mg QD in Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis Who are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID / Asthma/Allergy
Merck/i3 - Multicenter, Double-Blind, Placebo Controlled, Randomized, Parallel-Group Study to Evaluate the clinical Effect of Oral Montelukast Versus Placebo in Persistent Asthma which is also Active During allergy Seasons in Pediatric Patients with Seasonal Aeroallergen Sensitivity / Pediatric Allergy/Asthma
Merck & Co. - A Multicenter, Double-Blind, Randomized Study Investigating the Clinical Effect of Montelukast on Allergic Rhinitis in Patients With Seasonal Allergic Rhinitis and Chronic Asthma-Spring 2003 Study / Asthma-SAR
Integrated Therapeutic Group, Inc. - “12 Week study, Multicenter, Double-Blind, Placebo Controlled Effects of Treatment of SAR in Subjects With Co-Morbid Asthma and a History of Seasonal Exacerbations of Asthma on Medical Resources Utilization (for Asthma and SAR)” / Asthma SAR
Merck/i3 - Multicenter, Double-Blind, Placebo Controlled, Randomized, Parallel-Group Study to Evaluate the clinical Effect of Oral Montelukast Versus Placebo in Persistent Asthma which is also Active During allergy Seasons in Pediatric Patients with Seasonal Aeroallergen Sensitivity / Pediatric Allergy/Asthma
Merck & Co. - A Multicenter, Double-Blind, Randomized Study Investigating the Clinical Effect of Montelukast on Allergic Rhinitis in Patients With Seasonal Allergic Rhinitis and Chronic Asthma-Spring 2003 Study / Asthma-SAR
Integrated Therapeutic Group, Inc. - “12 Week study, Multicenter, Double-Blind, Placebo Controlled Effects of Treatment of SAR in Subjects With Co-Morbid Asthma and a History of Seasonal Exacerbations of Asthma on Medical Resources Utilization (for Asthma and SAR)” / Asthma SAR
Urticaria
Novartis - A multicenter, randomized, double-blind, placebo- controlled Phase 3 study of remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for 52 weeks in adult chronic spontaneous urticaria patients inadequately controlled by H1-antihistamines / Chronic Idiopathic Urticaria
ITGI - A Comparitive Double-Blind, Double-Dummy Study of Desloratadine (DL) 5mg Once Daily, Cetirizine 10mg Once Daily, and Placebo Once Daily in Patients with Chronic Idiopathic Urticaria (DIU) / Chronic Idiopathic Urticaria
ITGI - A Comparitive Double-Blind, Double-Dummy Study of Desloratadine (DL) 5mg Once Daily, Cetirizine 10mg Once Daily, and Placebo Once Daily in Patients with Chronic Idiopathic Urticaria (DIU) / Chronic Idiopathic Urticaria
Cold/Allergy
Boehrigner Ingleheim Pharm. - BI 244.2503 A phase IV Safety Trial in Pediatric Patients (Ages 2-5) with Rhinorrhea Associated with a Common Cold or Allergy / Pediatric Cold/allergy
Atopic Dermatitis
Fujisawa Healthcare, Inc. - “An Open-Label Study to Evaluate the Safety of Topically Applied Tacrolimus Ointment for the Treatment of Atopic Dermatitis” / Atopic Dermatitis